Figure 3.
Everolimus Effects as a Second-Line Treatment in Patient-Derived RCC Orthoxenografts
(A) Tumor progression of treatment with sunitinib or sunitinib followed by everolimus in Ren28 and Ren96 RCC PDX tumors starting at 1,000 mm3, and Corresponding Kaplan-Meier survival curves.
(B) Representative images of pS6 and S6kinase immunohistochemistry staining, and pS6, MCT4, MCT1, and MCT4 immunohistofluorescence staining, counterstained with DAPI (20× magnifications).
(C) Quantification of expression MCT1 and MCT4 in Ren28 and Ren96 in the different treatments as percentage of positive area per field, from four animals per treatment group, four images each.
(D) Quantification of metabolic symbiosis pattern in Ren28- and Ren96-treated tumors as presence of MCT1/MCT4 mutually exclusive pattern (symbiosis pattern) versus homogeneous, co-staining (no symbiosis pattern).